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ABSTRACT
Background and aim: Mucositis is a well-known side effect to chemotherapy treatment after breast cancer surgery. The number
of women who experience oral complication that is not classified as mucositis is less investigated as well as the impact of oral
complication on the women’s quality of life. Aim: To describe how many women with breast cancer report oral complications
during their adjuvant chemotherapy with Ebirubicin, Cyclophosphamide and Taxotere or Taxol, to describe which oral complica-
tions the women report and the impact the oral complication has on women’s daily life and quality of life.
Methods: A cross-sectional design was used. The women were invited to fill out a self-composed questionnaire at proximal 12
weeks after initiation of the treatment. The questionnaire had two scales to summarize information about oral complication and
their impact on daily living was used. The questionnaire has been face- and content validated. Internal consistency was between
0.76 to 0.83.
Results: All 101 women had experienced oral complications to some extent. A linear regression analysis has reviled that redness,
coaching and changes of taste explained 74% of reported reduction in quality of life. There was a positive correlation between the
sum of symptoms (number of symptoms and duration) and reported quality of life score r = .480 (p = .000).
Conclusions: Oral complications was experienced by all women who were treated with CT after breast cancer surgery. Red-
ness, coaching and changes of taste were significant contributors to reducing quality of life and need to be prevented during
chemotherapy.
Key Words: Mucositis, Chemotherapy treatment, Breast cancer surgery, Oral complication, Quality of life
1. BACKGROUND
Breast cancer is the most commonly occurring cancer in
women and the second most common cancer overall. There
were over 2 million new cases in 2018.[1] Denmark is among
the 25 countries with the highest rates of breast cancer in
2018.[1]
In Denmark a nationwide screening program was introduced
in 2008-2009, since then an increase in the number of newly
diagnosed case of breast cancer has been detected but it is ex-
pected that this increase is temporary. The primary treatment
for breast cancer is surgery combined with post-treatment
such as chemotherapy, radiation therapy, anti-hormonal treat-
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ment and/or treatment with the monoclonal antibody drug
Trastuzmab.[2]
The number of patients for primary surgery has been rel-
atively stable the last ten years but referrals to adjuvant
chemotherapy treatment have increased significantly. The ad-
juvant regime with chemotherapy for the treatment of breast
cancer is a combination of Epirubicin, Cyclophosphamide
and Docetaxel or Taxol.[2, 3] Chemotherapy (CT) interferes
with cellular metabolism of both malignant cells and normal
tissues.[4] Application of CT frequently causes severe ad-
verse effects. Oral symptoms as mucosal lesions/mucositis;
oral discomfort and pain; haemorrhage; salivary gland hypo-
function and oral dryness; taste disturbances; higher suscep-
tibility to bacterial, fungal, and viral infections; as well as
changes in the oral microflora to become potentially more
pathogenic has been linked to chemotherapy.[4] Oral compli-
cation is one of the most common side effects to CT and is
reported to be between 10%-100%.[3, 5–7] Studies that have
reported on oral complications of patients receiving CT have
included patients with a mix of cancer diagnoses such as
haematological cancer, patients who is going through a stem
cell transplantation, patients with head and neck cancer and
patients in radiotherapy.[3, 5–7] The occurrence, severity, and
duration of these oral adverse effects show a wide variability
depending on underlying cancer diagnosis and disease stage
in addition to different dose-intensities and combinations of
chemotherapeutic drugs.[4]
Mucositis is defined as inflammatory and/or ulcerative le-
sions of the oral and/or gastrointestinal tract.[8] One of the
major causes of mucositis is high-dose cancer therapy. Ali-
mentary tract mucositis refers to the expression of mucosal
injury across the continuum of oral and gastrointestinal mu-
cosa, from the mouth to the anus. From 21 studies including
2766 patients the OR for developing oral mucositis have been
estimated to range from 2.29 to 13.64 with a mean OR of
4.08 in women undergoing CT after breast cancer surgery.[8]
Oral complications can result in dry mouth, bad breath,
change of taste, reduced nutritional intake, pain, difficulty
speaking and social isolation.[9] Moreover, there is a risk
that the oral complication can lead to local infections such
as stomatitis and mucositis and further develop to a systemic
infection.[10, 11] Women which have been diagnosed mucosi-
tis have reported changes in taste.[12–15] Patients describe
that there was great individual variation in patterns, intensity
and impact of taste changes, with changes reported to have
ceased in all participants within 3.5 months after treatment
ended. While not all participants found reported changes
“bothersome,” those who did reported predominately emo-
tional and social consequences. Taste changes were said to
be influenced by, or to influence, other symptoms, for exam-
ple, appetite loss, nutritional intake, early satiation, nausea,
and oral problems.[12, 13, 15] Daily life was impacted substan-
tially when chemosensory and/or food-related changes were
experienced and the changes influenced altered food prefer-
ences, practical constraints in daily life, and impact on social
functioning.[12]
Oral complications can result in increased need for medica-
tion to relive the pain. Furthermore, oral complications have
been reported to negatively influence patient’s quality of life
through the impact on everyday life and oral complications
have been rated as one of the worst side effects to CT.[5, 9]
In addition, oral complications increase the costs of medi-
cation and can result in an extended hospitalization. Oral
complications can lead to extended period of treatment.[5, 6]
The adjuvant treatment is developed and adjusted, therefor
nurses have to update their guidance of patients in order to
prevent adverse effects or progression of side-effects caused
by the CT. No previous study as solely reported the inci-
dence of oral problems in women undergoing adjuvant CT
for breast cancer. Previously published clinical guidelines
have focused on prevention impact on daily living and treat-
ment of stomatitis or mucositis during CT. It is recommended
that patients assess their own mouth and report any complica-
tions, so treatment can be initiated early, and severe compli-
cations avoided and that patients understand the importance
of good oral hygiene prior to and during CT treatments.[8]
However, from our experience more women are suffering
from oral complication that those diagnosed with a stomatitis
or mucositis. To provide patients with relevant education
relating to oral care, and the impact on daily living more
detailed information is needed on what type of oral compli-
cation the women experience, the impact on daily living and
which preventive measure women initiate.
Thus, the aim of this study is to describe how many women
with breast cancer report oral complications during their ad-
juvant CT with Ebirubicin, Cyclophosphamide and Taxotere
or Taxol, to describe which oral complications the women
report and the impact the oral complication has on women’s
daily life and quality of life.
2. METHODS
At the oncological outpatient clinic at Aalborg university
Hospital, Denmark. The department treat approximately
300 women each year with adjuvant CT. The treatment is
standardized by the guideline for diagnostics, surgery, pathol-
ogy and oncology set out by The Danish Breast Cancer
Group (DBCG) and The national Board of Health.[2] The
CT is given as three treatments with Ebirubicin and Cy-
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clophosphamide every 3 week, followed by three treatments
with Taxotere every 3 week or nine weekly treatments with
Taxol.[2]
All women referred to adjuvant CT with Ebirubicin, Cy-
clophosphamide and Taxotere or Taxol in a nine months pe-
riod were consecutively included in the study. In this study,
101 women were included. Women who does not speak or
read Danish, women who had a psychiatric diagnose or were
diagnosed as demented were excluded.
2.1 Design
A cross-sectional design was used. The women were invited
to fill out a self-composed questionnaire at the fifth treatment
at proximal 12 weeks after initiation of the treatment. The
questionnaire was filled out during treatment and returned to
the staff in an envelope before the woman left the outpatient
clinic.
2.2 Instrument
A self-composed questionnaire with two scales to summa-
rize information about oral complication and their impact on
daily living was used. The items in each scale were included
after a search of the literature of reported oral cavity prob-
lems reported by patients during chemotherapy (4). Only
items related to the oral cavity were included. The “Oral
symptom scale” has seven items (Dry Mouth, Pain, Redness,
Coating, Wound, Changes in taste, Other complications) that
identify oral symptoms and the duration of the symptom.
Each item could be scored from “0” representing not having
the symptom to “4” representing have the symptom all the
time. The score on this scale represent “0” not having any of
the symptoms and maximum “28” having all the symptoms
all the time during the treatment.
“The oral symptom impact scale” has seven items that iden-
tify daily activities, (Have oral symptoms stopped you from:
Having something to drink, Drinking specific beverages;
Having something to eat, Eating specific food items; Have
you reduced your social interactions due to oral symptoms,
Stopped you form doing what you want in your daily life,
Reduced your quality of life).
Each item could be scored from “0” representing not having
the symptom to “4” representing have the symptom all the
time. The score on this scale represent “0” for not having
any symptoms that impacted daily living and maximum “28”
having all the symptoms that impacted all the arear measured
all the time during the treatment.
The questionnaire has been face- and content validated in
two steps.
In the process of content validation teen nurses and four
doctors working with women with breast cancer were asked
to evaluate the content and give suggestion to changes if
they had some. They were asked to rate the relevance of
each question from 1-5. One indicated “not relevant at all”
and five “very relevant”. The cut off point for changing a
question was set to 3.5. No questions were removed but a
few changes were incorporated into the questionnaire. Next
step was to present the questionnaire to ten women. They
were asked to fill in the questionnaire. After filling in the
questionnaire the women were interviewed about how they
understood each of the questions, the rating scale, how to
rate and whether all relevant options were given. Further-
more, the women were asked to evaluate the content of the
questionnaire by considering if all relevant topics about oral
complication were presented. Finally, the women were asked
if they wanted to add questions or respond options. Hereafter
the questionnaire was finalized.
Internal consistency was tested by Cronbach’s Alpha. The
score for “Oral symptom scale” was 0.76 and the score for
“The oral symptom impact scale” was 0.83.
2.3 Ethics
The women received written and oral information about the
study when the questionnaire was handed out. The infor-
mation stressed out that participation was voluntary, that
data would be treated confidentially and that they would be
anonymous in reporting of results. We only recorded the
number of eligible women, who received a questionnaire and
the number of questionnaires returned. If the woman did not
want to participate she could just return the questionnaire in
the closed envelope and it would have no influence on the
present or any future treatment. No reminders were given.
The study was approved but the local ethical committee and
The Danish Authorities for Data Surveillance under the file
no 2008-58-0028
2.4 Statistics
Data was processed in statistical package SPSS version 24.
Descriptive statistics was used. For ration and ration interval
scaled data means and SD are given. If data was normal
distributed Student t-test was used to tested for differences
if f-test showed non-normal distribution Mann-Whitney’s
rank sum test was used to test for differences between the
group p-value level below .05 was considered as significant.
A linear regression analysis was carried out using women’s
self-reported decrease in quality of life as the dependent
variable and self-reported oral symptoms as the predictor
(constant). Only results with a significant < .10 are reported.
Pearson correlation coefficient was used to calculate corre-
lation between sum of symptoms and changes in quality of
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life.
3. RESULTS
During the study period, 101 women were referred to adju-
vant CT. Their age was between 29 and 77 years with a mean
age of 54.9 (8.9). All women accepted to participate and
returned the questionnaires. Of the respondent 15% reported
to smoke and 84% were treated with Taxotere and 16% with
Taxol.
The women scored from one to 19 on the Oral symptom scale,
with a mean of 8.1 (4.5). The type of oral complication and
duration is presented in Table 1. The symptoms were re-
ported to start between day 0-9 with a mean of 3.5 (2.4) days
after the initiation of the treatment. The women reported that
the symptoms were most troublesome for a period of 0-35
days with a mean of 8.5 (5.5) days. Women receiving treat-
ment with Taxotere scored 9.0 (4.3) vs 3.8 (3.2) for women
treated with Taxol (p = .000). Smokers scored 7.4 (4.3) vs
non-smokers 8.6 (4.6) on the Oral symptom scale (p = .548).
All together 31 women reported other symptoms, such as
infections 6%, burning sensation in the oral cavity or tongue
4%, tooth ache 2%, sore lips 3%. The scores on the oral
symptom impact scored ranged from 0 to 20, 31% of the
women reported no impact on the daily living and the mean
score was 3.6 (4.2). The scores from each of the items of
impact on daily living are reported in Table 2. Smokers re-
ported a score of 3.5 (4.3) vs 3.9 (4.2) for non-smokers (p =
.819, Mann-Whitney). Women treated with Taxotere scored
4.2 (4.3) vs 0.8 (2.0) for women treated with Taxol (p = .000,
Mann-Whitney).
Table 1. Type of oral complication and duration during the adjuvant chemotherapy
 
 
Oral complication: 
Not at all  
[CI95] 
A little or some of the time  
[CI95] 
Most of or all the time  
[CI95] 
Dry mouth 
5.0%  
[1.64-11.28 ] 
50.5% 
[39.83-60.17] 
44.5% 
[34.08-54.28] 
Mouth pain 
57.0% 
[456.71-66.86] 
36.0% 
[26.64-46.21] 
7.0% 
[2.86-13.89] 
Redness  
56.3%  
[45.72-65.92] 
39.4% 
[29.40-49.27] 
6.3% 
[2.23-12.60] 
Coatings  
30.3% 
[21.24-39.98] 
49.5% 
[38.86-59.20] 
20.2% 
[12.67-30.29] 
Wound 
83.5% 
[74.18-89.77]  
14.5% 
[7.87-22.37] 
2.0% 
[0.24-7.04] 
Changes in taste 
13.3% 
[7.11-21.20] 
36.8% 
[26.64-46.21] 
20.2% 
[12.67-29.19] 
Other complications 
71.8%  
[61.07-79.64] 
19.2% 
[11.84-28.07] 
8.9% 
[4.20-16.40] 
 
Table 2. The impact of oral problems reported by women treated with adjuvant chemotherapy after surgery for breast cancer
 
 
Impact on daily life 
Not at all  
[CI95] 
A little or some 
of the time 
Most of or all the time   
Have oral symptoms stopped you form having something 
to drink? 
Have you avoided specific beverages due to oral 
symptoms? 
81.2% 
[71.93-88.16] 
50.5% 
[39.83-60.17] 
16.4% 
[9.43-24.68] 
34.3% 
[24.82-44.15] 
2.0% 
[0.24-7.04] 
12.5% 
[6.36-20.02] 
Have oral symptoms stopped you form having something 
to eat? 
Have you avoided specific food items due to oral 
symptoms? 
63.4% 
[52.76-72.44] 
61.5% 
[50.73-70.60] 
32.7% 
[23.02-42.08] 
27.1% 
[18.61-36.80] 
4.0% 
[1.10-9.93] 
1.0% 
[0.03-5.45] 
Have you reduced your social interaction due to oral 
symptoms? 
90.0% 
[82.38-95.10]  
9.%1 
[4.20-16.40] 
0% 
[0.00-3.62]  
Is your quality of life been reduced due to oral symptoms? 
49.0% 
[38.86-59.20] 
45.0% 
[35.03-55.27] 
6.0% 
[2.23-12.60] 
Have oral symptoms stopped you from doing what you 
want to do in your daily life? 
86.0% 
[77.63-92.13] 
13.0% 
[7.11-21.20] 
1.0% 
[0.03-5.45] 
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The summarized mean symptom score was 8.1 (4.5). Women
who did not report a reduction in quality of life score 5.8
(4.0) vs 11.8 (3.9) for women who reported that their quality
of life was reduced most of the time (p = .001). There was a
positive correlation between the sum of symptoms (number
of symptoms and duration) and reported quality of life score
r = .480 (p = .000).
A linear regression analysis was carried out having the
women’s’ score of Quality of Life as the dependent vari-
able and the specific oral symptoms as independent variables.
The results of the linear regression analysis indicated that
oral symptoms were a significant predictor of reduced quality
of life among women undergoing adjuvant chemotherapy (F
= 7.722, p-value ≤ .000 with an R2 of 0.356) In Table 3 the
result of the regression analysis is reported. Three symptoms,
Coating, redness and changes of taste, accounted for 74% of
the reduction in women’s reported quality of life.
Table 3. Regressions analysis (Dependent variable:
Reduced Quality of Life)
 
 
Model β p value  
Dry mouth -.101 .317 
Mouth pain 0.072 .548 
Rediness 0.222 .049 
Coatings 0.271 .013 
Wounds 0.007 .939 
Changes in taste 0.256 .018 
 
4. DISCUSSION
This study is the first, to our knowledge, to describe and give
an insight into how many women with breast cancer is devel-
oping oral complications during their adjuvant chemotherapy
with Ebirubicin, Cyclophosphamide and Taxotere or Taxol.
All 101 women who participated in the study had some kind
of oral complications as a side effect while treated with adju-
vant chemotherapy. However, there was a large variation in
the occurrence of the various types of oral symptoms. The
regression analysis revealed that coating and changes of taste
had the highest impact on women’s reported reduction in
quality of life due to symptoms from the oral cavity.
Previous studies have reported the OR for developing of
mucositis to be approximately 4% in women receiving
chemotherapy after surgery for mamma cancer.[8] However,
mucositis is an inflammatory and or ulcerative lesion of the
oral tract,[8] which only embrace a part of the oral symp-
toms experienced by the women. Furthermore, 95% of the
women in this study reported having dry mouth for a shorter
or longer period during the treatment. As saliva constitutes
an important part of the mouth’s immune system and thus
prevents inflammation of the mouth it is important to identify
and to prevent this symptom.[16] Only identifying women
with diagnosed mucositis might overlook a high number of
women that could develop problems.
Taste changes are common side effects in cancer patients
undergoing chemotherapy treatments. This can lead to a
reduced food enjoyment and an inadequate nutrient intake
with a high impact on nutritional status and quality of life.[17]
During chemotherapy for breast cancer it is reported that up
to 80% of women have noticed a change in their sense of
taste.[17, 18] This could contribute to reduce women’s intake
of food and drink and lead to a significant reduction in the
intake of energy and protein causing significant reduction
in BMI during the treatment.[15] In our study approximately
50% of women reported that oral symptoms had an impact
on what they chose to drink and 28% reported that their
choice of food items were impacted. It is important that
the nutritional state is maintained, and the staff are aware
of the risk that patients do not receive adequate nutrition.[16]
As chemotherapy is given in the outpatient clinic patients
could be advised to monitor their weight and discuss weight
changes with the staff.
Oral symptoms in this study has been reported to range from
from 2 days up to 35 days. For some of the women the oral
complications were present throughout the course of treat-
ment. The results are in line with what has been reported
by others[15] that the symptoms peak at two weeks after the
onset of treatment.
In a study evaluating how quality of life is affected by oral
complications,[19] oral complications are described as the
most significant side effect for chemotherapy and radiation
therapy. This study shows that one of the causes of reduced
quality of life due to oral complications is that these compli-
cations make it difficult to chew and sink food, gives taste
changes, make it difficult to speak and causes pain.[19] How-
ever, women with breast cancer were not included in the
study.[19] In our study 14% of the women reported that they
stopped doing something in their daily lives due to the oral
complications and 51% reported a reduction in quality of
life. A linear regression analysis has reviled that redness,
coaching and changes of taste are significant contributors to
reducing quality of life and explain 74% of the reduction in
the quality of life score. Being a cancer patient is difficult
and challenging. Therefore, it is of great important to prevent
unnecessary complications and their impact on the outcomes
of the treatment, even though the complications might seem
to be minor.
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4.1 Strength and limitation
We used a self-composed but validated questionnaire that all
women who were included filled out and returned. Women re-
ported only the symptoms from the oral cavity omitting other
known side effects from chemotherapy, such as changes in
smell. As women had the opportunity to report both specific
and other symptoms from the oral cavity, we anticipate that
we have captured the symptoms from the oral cavity women
experiences, when going true chemotherapy. The collected
data and the subsequent analysis of the results provide a gen-
eral knowledge in relation to the research question. In order
to upgrade the study further, qualitative data collection in
the form of interviews of some respondents could help in a
deeper understanding of the quantitative data as an interview
could provide insight into the patient’s perspective in relation
to the sensations experienced. An interview survey based
on the collected data from the questionnaire survey could
help to refine and explain the quantitative data by exploring
the patients’ perspective in more detail. It could have given
the study of oral complications a more nuanced and detailed
picture of the meaning that oral complications have had for
women during treatment with preventive chemotherapy.
5. CONCLUSION
Oral complications are experienced by all women who are
treated with CT after breast cancer surgery. Redness, coach-
ing and changes of taste are significant contributors to re-
ducing quality of life. Furthermore, a significant correlation
between the number and duration of symptoms was estab-
lished.
5.1 Implications for practice
The study provides insight into which oral cavity problems
the women experienced and how it affected their daily liv-
ing and quality of life. These results can be used to build
upon existing literature on oral cavity problems and result
in providing nursing supportive care. But further studies are
needed in order to get a more solid foundation for the impact
and development of oral symptoms. This simple question-
naire could be used as a guide for nurses when assessing
oral cavity symptoms in women having chemotherapy after
breast cancer surgery.
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